Steroid hormone receptors, matrix metalloproteinases, insulin-like growth factor, and dystroglycans interactions in prostatic diseases in the elderly men

Microscopy Research and Technique

Volumn 75, Issue 9, 2012, Pages 1197-1205

  Hetzl, A C ^a   Favaro W J ^a   Billis, A ^a   Ferreira, U ^a   Cagnon, V H A ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Aging; Dystroglycans; Growth factors; Hormone interactions; Insulin like growth factors; Matrix metalloproteinases; Prostate; Prostatic diseases; Steroid hormones

Indexed keywords

BLOOD VESSELS; INSULIN; PROTEINS; STEROID HORMONES; UROLOGY;

DYSTROGLYCAN; GROWTH FACTOR; HIGH GRADES; HORMONE INTERACTION; INSULIN-LIKE GROWTH FACTOR; MATRIX; MATRIX METALLOPROTEINASE; METALLOPROTEINASES; PROSTATE; PROSTATIC DISEASE;

MOLECULES;

EID: 84865425492     PISSN: 1059910X     EISSN: 10970029     Source Type: Journal    
DOI: 10.1002/jemt.22049     Document Type: Article

References (36)

1. Bao X, Fukuda M. 2010. A tumor suppressor function of laminin-binding alpha-dystroglycan. Methods Enzymol 479: 387-396.
2. Brennan PA, Jing J, Ethunandan M, Gorecki D. 2004. Dystroglycan complex in cancer. Eur J Surg Oncol 30: 589-592.
3. Carruba G. 2007. Estrogen and Prostate Cancer: An eclipsed truth in an androgen-dominated scenario. J Cell Biochem 102: 899-911.
4. Cross S, Lippitt J, Mitchell A, Hollingsbury F, Balasubramanian SP, Reed MW, Eaton C, Catto JW, Hamdy F, Winder SJ. 2008. Expression of β-dystroglycan is reduced or absent in many human carcinomas. Histopathology 53: 561-566.
5. Cunha GR, Hayward SW, Wang YZ. 2002. Role of stroma in carcinogenesis of the prostate. Differentiation 70: 473-485.
6. Denley A, Cosgrove LJ, Booker GW, Wallace JC, Forbes BE. 2005. Molecular interactions of the IGF system. Cytokine Growth Factor Rev 16: 421-439.
7. Djavan B, Waldert M, Seitz C, Marberger M. 2001. Insulin-like growth factors and prostate cancer. World J Urol 19: 225-233.
8. Esser AK, Cohen MB, Henry MD. 2010. Dystroglycan is not required for maintenance of the luminal epithelial basement membrane or cell polarity in the mouse prostate. Prostate 70: 777-787.
9. Giannelli G, Falk-Marzillier J, Schiraldi O, Stetler-Stevenson WG, Quaranta V. 1997. Induction of cell migration by matrix metalloproteinase-2 cleavage of laminin-5. Science 277: 225-228.
10. Härkönen PL, Mäkelä SI. 2004. Role of estrogens in development of prostate cancer. J Steroid Biochem Mol Biol 92: 297-305.
11. Henry MD, Cohen MB, Campbell KP. 2001. Reduced expression of dystroglycan in breast and prostate cancer. Hum Pathol 32: 791-795.
12. Hosokawa H, Ninomiya H, Kitamura Y, Fujiwara K, Masaki T. 2002. Vascular endothelial cells that express dystroglycan are involved in angiogenesis. J Cell Sci 115: 1487-1496.
13. Hsing AW, Reichardt JKV, Stanczyk FZ. 2002. Hormones and prostate cancer: Current perspectives and future directions. Prostate 52: 213-235.
14. Imamov O, Shim GJ, Warner M, Gustafsson JA. 2005. Estrogen receptor Beta in health and disease. Biol Reprod 73: 866-871.
15. Kabashima A, Maehara Y, Kakehi Y. 2000. Clinicopathological features and over-expression of matrix metalloproteinases in intramural gastric carcinoma with lymph node metastasis. Clin Cancer Res 6: 3581-3584.
16. Kamijima K, Burt T, Cohen G, Arano I, Hamasaki T. 2006. A placebo-controlled, randomized withdrawal study of sertraline for major depressive disorder in Japan. Int Clin Psychopharmacol 21: 1-9.
17. Latil A, Bièche I, Vidaud D, Lidereau R, Berthon P, Cussenot O, Vidaud M. 2001. Evaluation of androgen, estrogen (ERα and ERβ), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. Cancer Res 61: 1919.
18. Leav I, Lau KM, Adams JY, McNeal JE, Taplin ME, Wang J, Singh H, Ho SM. 2001. Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am J Pathol 159: 79-92.
19. London CA, Sekhon HS, Arora V, Stein DA, Iversen PL, Devi GR. 2003. A novel antisense inhibitor of MMP-9 attenuates angiogenesis, human prostate cancer cell invasion and tumorigenicity. Cancer Gene Ther 10: 823-832.
20. Lynch C, Matrisian L. 2002. Matrix metalloproteinases in tumor-host cell communication. Differentiation 70: 561-573.
21. Marcelli M, Cunningham G. 1999. Hormonal signaling in prostatic hyperplasia and neoplasia. J Clin Endicrinol Metab 84: 3463-3468.
22. Markopoulos AK, Poulopoulos AK, Kayavis I, Papanayotou P. 2000. Immunohistochemical detection of insulin-like growth factor-I in the labial salivary glands of patients with Sjögren's syndrome. Oral Dis 6: 31-34.
23. Martin MD, Matrisian LM. 2007. The other side of MMPs: Protective roles in tumor progression. Cancer Metastasis Rev 26: 717-724.
24. Montgomery DC. 1991. Design and analysis of experiments. New York: Wiley. pp. 649.
25. Mostofi, FK, Price EB, Jr. 1973. Tumors of the male genital system, atlas of tumor pathology, Second Series, Fascicle 8. Washington DC: Armed Forces Institute of Pathology. Pp. 202-217.
26. Ockrim J, Lalani EL-N, Abel P. 2006. Therapy Insight: Parenteral estrogen treatment for prostate cancer-A new dawn for an old therapy. Nat Clin Pract Oncol 10: 552-563.
27. Pavelic J, Matijevic T, Knezevic J. 2007. Biological and physiological aspects of action of insulin-like growth factor peptide family. Indian J Med Res 125: 511-522.
28. Rowlands MA, Holly JM, Hamdy F, Phillips J, Goodwin L, Marsden G, Gunnell D, Donovan J, Neal DE, Martin RM. 2012. Serum insulin-like growth factors and mortality in localized and advanced clinically detected prostate cancer. Cancer Causes Control 23: 347-354.
29. Shimojo H, Kobayashi M, Kamigaito T, Shimojo Y, Fukuda M, Nakayama J. 2011. Reduced glycosylation of α-dystroglycans on carcinoma cells contributes to formation of highly infiltrative histological patterns in prostate cancer. Prostate 71: 1151-1157.
30. Sgambato A, Migaldi M, Montanari M, Camerini A, Brancaccio A, Rossi G, Cangiano R, Losasso C, Capelli G, Trentini GP, Cittadini A. 2003. Dystroglycan expression is frequently reduced in human breast and colon cancers and is associated with tumor progression. Am J Pathol 162: 849-860.
31. Sgambato A, De Paola B, Migaldi M, Di Salvatore M, Rettino A, Rossi G, Faraglia B, Boninsegna A, Maiorana A, Cittadini A. 2007. Dystroglycan expression is reduced during prostate tumorigenesis and is regulated by androgens in prostate cancer cells. J Cell Physiol 213: 528-539.
32. Tomas D, Kruslin B. 2004. The potential value of (Myo)fibroblastic stromal reaction in the diagnosis of prostatic adenocarcinoma. Prostate 61: 324-331.
33. Toorians AW, Kelleher S, Gooren LJ, Jimenez M, Handelsman DJ. 2003. Estimating the contribution of the prostate to blood dihydrotestosterone. J Clin Endocrinol Metab 88: 5207-5211.
34. Vermeulen A, Kaufman JM, Goemaere S, Van Pottelberg I. 2002. Estradiol in elderly men. Aging Male 5: 98-102.
35. Weihua Z, Makela S, Andersson LC, Salmi S, Saji S, Webster JI, Jensen EV, Nilsson S, Warner M, Gustafsson JA. 2001. A role for estrogen receptor beta in the regulation of growth of the ventral prostate. Proc Natl Acad Sci USA 98: 6330-6335.
36. Weihua Z, Warner M, Gustafsson JA. 2002. Estrogen receptor beta in the prostate. Mol Cell Endocrinol 193: 1-5.